CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018
|
|
- Darcy Price
- 5 years ago
- Views:
Transcription
1 CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018
2 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm Factory Tour Perlen Packaging 4.30 pm Aperitif CPH Presentation 13. September
3 CPH Chemie + Papier Holding AG Investor Presentation Perlen, 13 th September 2018
4 Contents 1 The CPH Group 2 Investment Case 3 Financial Performance CPH Presentation 13. September
5 The CPH Group At a Glance CPH is a diversified Swiss-based and internationally active industrial group that was founded in The shares of its holding company CPH Chemie + Papier Holding AG have been traded on the SIX Swiss Exchange since 2001, and its founding families remain anchor shareholders today. Business divisions Chemistry Packaging Paper 16% 28% 56% Production locations CH, DE, USA, CN, BRA, BiH Net sales in CHF million EBITDA in CHF million Balance sheet total in CHF million Equity ratio 57% Net debt / EBITDA 1.2x Personnel CPH Presentation 13. September
6 The CPH Group Business Divisions Division % of total net sales Chemistry 16% Paper 56% Packaging 28% Products Molecular sieves Chromatography gels Newsprint paper Magazine paper PVC mono films Coated PVdC films Strategy Differentiation Cost leadership Differentiation Brand CPH Presentation 13. September
7 The CPH Group Business Divisions Division Key figures 2017 Chemistry Paper Packaging Net sales: EBITDA: Production sites: Employees: CHF 75.5 million CHF 7.3 million CH / USA / CN / BiH 302 CHF million CHF 9.1 million CH 345 CHF million CHF 15.5 million CH / DE / USA / BRA / CN 363 Net sales 2017 by region 7% Switzerland 27% Rest of Europe 45% The Americas 20% Asia 1% Rest of the world 15% Switzerland 81% Rest of Europe 1% Americas 3% Asia 6% Switzerland 62% Rest of Europe 16% Americas 15% Asia 1% Rest of the world CPH Presentation 13. September
8 The CPH Group H1 Divisional Income Statements CPH Group Chemistry Paper Packaging in CHF million H1 17 H1 18 H1 17 H1 18 ± in % H1 17 H1 18 ± in % H1 17 H1 18 ± in % Net sales EBITDA EBITDA margin in % EBIT n.a EBIT margin in % Personnel CPH Presentation 13. September
9 The CPH Group Worldwide Operations 2017 net sales by region 78% Europe 12% The Americas 9% Asia 1% Rest of the world 2017 net sales by division 16% Chemistry 56% Paper 28% Packaging CPH Presentation 13. September
10 The CPH Group Strategic Objectives Objective Balanced shares of net sales among the three business divisions Higher proportion of net sales generated outside Europe Less dependency on the Swiss franc in currency terms Action Expand Chemistry and Packaging Divisions as counterbalance to Paper Expand business in markets in growth regions Expand production capacities outside Switzerland 44% 22% 70% Result 36% 16% 36% Shares of Chemistry and Packaging in total net sales Proportion of net sales generated outside Europe Proportion of total costs incurred in Swiss francs CPH Presentation 13. September
11 Contents 1 The CPH Group 2 Investment Case 3 Financial Performance Appendix CPH Presentation 13. September
12 The CPH Group Investment Case 01 Leading market position with autonomous brands in three industrial fields 02 Diversified portfolio of products and applications provided to a longstanding customer base 03 Achieve and maintain cost leadership in the paper sales markets, sole Swiss recycler of recovered paper 04 Expansion of chemistry and packaging divisions reducing exposure to paper and lowering currency movement risks 05 Financial profile showing results of corporate strategy implementation 06 Solid equity base and stable anchor shareholders with a long-term commitment CPH Presentation 13. September
13 1 Leading market position with autonomous brands in three industrial fields Division Chemistry Paper Packaging Positioning Number 3 worldwide for molecular sieves for industrial applications Number 1 in Switzerland for newsprint & magazine paper and waste paper recycling Number 3 worldwide for coated barrier films for pharmaceutical applications Brand CPH Presentation 13. September
14 2 Diversified portfolio of products and applications provided to a longstanding customer base Chemistry Paper Packaging Main markets Industry, Energy, Pharmaceuticals Main markets Publishing Main markets Pharmaceuticals CPH Presentation 13. September
15 3 Achieve and maintain cost leadership in the paper sales markets, sole Swiss recycler of recovered paper Procurement Production Sales Water Own sources Recovered paper Former Utzenstorf volumes and sorting facility Logistics Transport Market Electricity Liberalized market Biomass power plant Own hydro power plant Heat Steam from Renergia The PM7: Europe s most advanced paper machine Productivity Production volume in tonnes +74% Personnel required -12% Fixed costs in CHF -1% Cost per tonne -32% Sustainability CO 2 emissions in tonnes down to Almost carbon-neutral operation CPH Presentation 13. September
16 4 Expansion of Chemistry and Packaging Divisions reduce the exposure to paper and lower currency movement risks November 2015 March 2016 June 2016 June 2017 August 2017 October 2017 Zeochem acquires molecular sieve manufacturer ALSIO of China. Zeochem sells its Uetikon operating facility to the Canton of Zurich Perlen Packaging expands to China, opening a new coatings production plant Fertilizer production ceases at the Uetikon site after 137 years. Capacities expanded at Zeochem USA for producing molecular sieves used to purify oxygen. Zeochem takes over the business activities of Armar and strengthens its deuterated products segment. November 2017 January 2018 March 2018 August 2018 Zeochem s new production plant in Zvornik in Bosnia- Herzegovina commences operations. Perlen Packaging acquires Sekoya of Brazil and plans new finishing plant for Zeochem acquires the molecular sieve distribution activities of Yusheng Chemical in China. Zeochem moves the production of deuterated products to the new location in Rüti. According to strategic targets CPH Presentation 13. September
17 5 Financial profile showing results of corporate strategy implementation % % % 300 9% 200 6% 100 3% H Net sales (CHF millions) EBITDA margin (%) 0% CPH Presentation 13. September
18 6 Solid equity base and stable anchor shareholders with a long-term commitment Equity ratio development Shareholder base (as of 31 December 2017) 100% 1,7% 5,6% 5,0% 7,2% 80% 49,9% 60% 40% 30,6% 20% 0% H Uetikon Industrieholding Public shareholders Ella Schnorf-Schmid J. Safra Sarasin Investmentfonds BoD, GEM and related parties Others CPH Presentation 13. September
19 Contents 1 The CPH Group 2 Investment Case 3 Financial Performance Appendix CPH Presentation 13. September
20 The CPH Group Key Figures in CHF million FY 2016 FY 2017 ± in % H H ± in % Net sales EBITDA % % % % EBIT % % % % Net result (including minorities) % % n.a % % n.a. Cash flow Free cash flow Balance sheet total Equity % % % % +5.8 Personnel CPH Presentation 13. September
21 Chemistry Business Development Net sales EBITDA % 16% 12% 8% 4% H H1 18 0% CHF million CHF million % of net sales 2017 net sales by region 1st half of % Switzerland 27% Rest of Europe 45% Americas 20% Asia 1% Rest of the world Zvornik production ramped up US and Chinese facilities fully utilized Acquisition of molecular sieve distribution activities of Yusheng Chemical in China Armar integrated Manufacture of deuterated products moved to Rüti in summer 2018 CPH Presentation 13. September
22 Paper Business Development Net sales H1 18 EBITDA H % 15% 10% 5% 0% -5% CHF million CHF million % of net sales 2017 net sales by region First half of % Switzerland 81% Rest of Europe 1% Americas 3% Asia Broad balance in supply and demand prompts higher paper prices Waste paper activities of Papierfabrik Utzenstorf successfully integrated into the new APS Altpapier Service Schweiz AG Positive impact of currency exchange rate trends CPH Presentation 13. September
23 Packaging Business Development Net sales EBITDA % 16% 12% 8% 4% H1 18 0% CHF million CHF million % of net sales 2017 net sales by region First half of % Switzerland 62% Rest of Europe 16% Americas 15% Asia 1% Rest of the world Record order volumes Capacities in Europe fully utilized; further transfer of work orders to China Expansion into Latin America through new holding in Sekoya of Brazil BLISTair single-use powder inhaler earns World Packaging Award CPH Presentation 13. September
24 The CPH Group Consolidated Balance Sheet in CHF million ± in CHF ± in % Liquid funds Other current assets Fixed assets Total assets Current liabilities Long-term liabilities Equity Total equity and liabilities CPH Presentation 13. September
25 The CPH Group Consolidated Cash Flow Statement in CHF million FY 2016 FY 2017 ± in % H1 17 H1 18 ± in % Net result (including minorities) n.a n.a. Depreciation, amortization, change in provisions Cash flow Change in net working capital Cash flow from operating activities Cash flow from investment activities n.a n.a. Free cash flow Financial and other long-term liabilities , Dividends to shareholders Cash flow from financing activities n.a n.a. Currency translation effects Net change in cash and cash equivalents n.a. CPH Presentation 13. September
26 The CPH Group Net Debt and Leverage Leverage development Net financial debt in 2017 (CHF in millions) 8,0x 200 6,0x 6,6x , ,0x 2,0x 2,2x 2,2x 1,2x , H1 18 Net debt / EBITDA 0 Financial liabilities Liquid funds + securities Net financial debt Comments Leverage strongly reduced over the past two years Net debt reduced by 11% in 2017 (82.1 => 73.1) Net debt H1 18 close to 2017 level despite CHF 24.5 million investments in business activities H1 18 Free cash flow before investments in business activities on high level (CHF 25.4 million) Net financial debt in H1 18 (CHF in millions) , , Financial liabilities Liquid funds + securities Net financial debt CPH Presentation 13. September
27 Outlook Optimistic for 2018 Chemistry Paper Packaging Conclusion of strategic realignment Transfer to Rüti of deuterated product manufacture Higher net sales and substantially improved earnings expected Newsprint and magazine paper prices expected to remain stable, but demand will continue to decline in the medium term Tangible improvements expected in net sales and earnings results Further expansion of production in Asia Integration of Sekoya and entry into service of finishing plant in Brazil Positive business trends and much-improved earnings expected CPH Group The newly-acquired companies should have a positive effect on net sales volumes in all three business divisions. Provided currency exchange rates remain stable, the CPH Group expects to report higher total net sales and an earnings result for 2018 as a whole that is a substantial improvement on the previous year. CPH Presentation 13. September
28 Outlook Target Key Performance Indicators Annual organic net sales growth of 3% in the medium term Equity ratio of over 50% EBITDA margin of over 10% Liquidity of at least CHF million Long-term average capital spending of CHF million a year Dividend policy: payout ratio of 30-50%, depending on free cash flow CPH Presentation 13. September
29 Any Questions Thank you for your attention CPH Presentation 13. September
1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationColoplast A/S. Investor presentation 1H 2005/06
Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound
More informationHyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai
More informationBALCHEM CORPORATION. Q Investor Relations Presentation
BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationEndesa 1Q 2017 Results 09/05/2017
Endesa 1Q 2017 Results 09/05/2017 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2 1. Highlights and key financial figures
More informationJTI Switzerland. JTI Schweiz 3
JTI Schweiz 3 Who we are 300 employees JTI has been manufacturing tobacco products in the Wiggertal area for over 45 years. The local market organization and the production facility in Dagmersellen (canton
More informationFY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009
FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)
More informationQ Investor Kit JANUARY-MARCH 2013
Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationQ Investor Kit JANUARY-JUNE 2013
Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationQ Investor Kit JANUARY-JUNE 2014
Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationTelekom Austria Group Results for the 1st Quarter May 27, 2003
Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationStraumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America
Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset
More informationThird-quarter results 2013
Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen
More informationConsolidated: Financial Summary
FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationSummary of Results for the First Half of FY2015/3
Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationELICA 2012 Q3 RESULTS. November 14,
ELICA ELICA 1 Q3 12 Highligths Negative market demand, showing better trend compared to previous quarters Group sales over performing in all major markets Cost reduction efforts and continued product innovation
More informationDIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
More informationDynamic Growth. Investora Gerhard Mahrle CFO COLTENE Holding AG. September 2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN. Investora 2018 Dynamic Growth Gerhard Mahrle CFO COLTENE Holding AG September 2018 COLTENE AN INTERNATIONALLY
More informationQ2 INVESTOR KIT JANUARY-JUNE 2011
Q2 INVESTOR KIT JANUARY-JUNE 2011 Swedish Match reporting segments Reporting segments following the transaction with STG on October 1, 2010 Snus and snuff - Swedish snus in Scandinavia and US - US moist
More informationLeading Intimate Healthcare. Investor presentation Q1 2007/08
Leading Intimate Healthcare Investor presentation Q1 2007/08 1 2 Agenda Introduction to Coloplast Q1 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate healthcare Appendices Q1
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More informationQ Investor Kit January December 2014
Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January
More informationResults Briefing. 15 ~ 17 May 2007
Results Briefing 1Q Q & 3 Months ended 31 Mar. 2007 15 ~ 17 May 2007 Content Key highlights Financial Corporate Financial results Industry overview Q&A Appendix 2 2 Key Highlights for the Period Key Highlights
More informationSolvay expands its specialty polymers offerings with Ryton PPS acquisition
Solvay expands its specialty polymers offerings with Ryton PPS acquisition Sustained strategic portfolio realignment With Ryton PPS* acquisition, Solvay further strengthens unmatched leadership in Specialty
More informationPresentation of. Burgdorf, 1 st November 2012
Presentation of Semi-Annual Results 2012/13 Burgdorf, 1 st November 2012 Important Notice The information contained in this document has not been independently verified and no representation or warranty,
More informationVITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar
VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar 2018-08-16 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION A Swedish
More informationVITROLIFE AB (PUBL) Pareto Securities Health Care Conference
VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION
More informationKey figures (consolidated)
Nestlé Group 2013 Key figures (consolidated) In millions of CHF (except for data per share) 2013 Results Sales 92158 Trading operating profit 14047 as % of sales 15.2% Profit for the year attributable
More information1Q2005. Hera Group presentation
1Q2005 Hera Group presentation 1 Y2005 has been characterized by a stream of achievements: Corporate Governance A new BoD was appointed in April. Further penetration of the Hera Gas market: 1,500 new clients
More informationBuilding a new model of sustainable chemistry. Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO
Building a new model of sustainable chemistry Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO Solvay at a glance Acceleration of Solvay s transformation Delivery in a challenging economic
More informationFIRSTQUARTER2018 RESULTSPRESENTATION
FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection
More informationValue creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO
Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue
More information1Q 2015 Results A Positive Start to 2015
1Q 2015 Results Main Events Operating Results Order Backlog Financial Performance Update on Disposal 1Q 2015 Results A Positive Start to 2015 Rome - May 14, 2015 1Q 2015 Main Backlog Events 1Q 2015 Results
More informationSüdzucker Group Capital market forum Rhine Neckar
Südzucker Group Capital market forum Rhine Neckar Mannheim, 7 November 2017 Thomas Kölbl (CFO) Südzucker Group, page 1 Südzucker Group at a glance Global operating German food group with long-standing
More informationLetter to Shareholders SEMI-ANNUAL REPORT 2008
Letter to Shareholders SEMI-ANNUAL REPORT 2008 Dear Shareholder You have in your hand the first shareholder letter issued by Nobel Biocare. Thanks to the conversion of Nobel Biocare s bearer shares into
More informationFIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO
FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO DISCLAIMER This document contains certain forward-looking information that is subject toa number of factors that may influence the accuracy of
More informationKAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO
KAPITALMARKNADSDAG 20 SEPTEMBER 2016 Thomas Axelsson, CEO 1 AGENDA 16.10-16.30 VD har ordet Thomas Axelsson, CEO 16.30-16.50 Clinical relevance of time-lapse Dr. Niels B. Ramsing, Business Unit Time-lapse,
More information1Q 2014 Earnings Release
1Q 2014 Earnings Release April 2014 DISCLAIMER Financial results for 1Q 2014 are provisional and accordingly subject to change according to the outside independent auditors review. This presentation contains
More informationSumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical
For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo
More informationEnel Américas 1Q 2018 results
Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation
More informationSpiros Nomikos Chief Executive Officer Solvay Sodi Bulgaria
Spiros Nomikos Chief Executive Officer Solvay Sodi Bulgaria FINANCIAL TIMES INVESTING IN BULGARIA CONFERENCE Investment Opportunities in Bulgaria The Case of Solvay Sodi Spiros Nomikos CEO of Solvay Sodi
More informationFor personal use only
ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting
More informationA GLOBAL LEADER IN PERSONALIZED NUTRITION
A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking
More informationBusiness Results. for the First Quarter of FY2016/3. August 4, 2015 (Tue.) NH Foods Ltd.
Business Results for the First Quarter of FY216/3 August 4, 215 (Tue.) NH Foods Ltd. Contents Contents I. Consolidated Business Results for FY216/3 1Q (Apr. Jun.) II. Outlook for FY216/3 III. Consolidated
More informationColoplast A/S. Investor Presentation 2005/06
Coloplast A/S Investor Presentation 2005/06 2 Coloplast in brief Coloplast s products and services help patients achieve greater independence from medical challenges in 4 areas, ostomy care, urology &
More informationTHIRD QUARTER REPORT 2011 (UNAUDITED)
THIRD QUARTER REPORT 2011 (UNAUDITED) Kronprinsesse Märthas pl. 1, Vika, 0166 Oslo, Norway. Tel: + 47 23 01 09 60, www.bionorpharma.com Page 1 THIRD QUARTER REPORT 2011 HIGHLIGHTS On the 25th August Bionor
More informationQ Investor Kit January December 2015
Q4 2015 Investor Kit January December 2015 Summary and Overview 2 Q4 and full year 2015: Headline numbers Sales for the full year increased by 9 percent and for the fourth quarter by 5 percent. In local
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationAPPLIANCE TELECOMMUNICATIONS
May 2001 1 DEVICE CRT PDP CRT components APPLIANCE Air Conditioner Refrigerator Washing machine Cooking appliance DISPLAY& MEDIA TV / Monitor CD-ROM DVD products VCR / PC / PCB TELECOMMUNICATIONS Switching
More informationInvestor Presentation. Q April 26, 2018
Investor Presentation Q3 2018 April 26, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities
More informationLeading Intimate Healthcare
21 May 2008 1 Leading Intimate Healthcare Investor presentation H1 2007/08 2 Agenda Introduction to Coloplast First 6 months 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate
More informationWalgreens (WAG) Analyst: Juan Fabres Fall 2014
Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores
More informationUroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011
Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating
More informationFinancial Presentation
Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with
More informationMerrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004
Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Disclaimer 2 This presentation contains forward-looking statements, i.e., current estimates or expectations
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More information1Q2017 法人說明會 Jun. 9, 2017
1Q2017 法人說明會 Jun. 9, 2017 FE group business Span over 10 major industries Own over 240 companies Established in 1937 9 public listed companies in Taiwan and HK Petrochemical & energy Polyester & synthetic
More informationFor personal use only
Australian Securities Exchange Limited Companies Announcements Office SYDNEY 4 April, 2012 New Australian Drug Developer Lists on ASX Key points Growth-focused Australian drug and therapeutic development
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationInvestor Presentation
Investor Presentation Forward Looking Statements The information presented herein may contain projections, predictions, estimates and other forwardlooking statements within the meaning of Section 27A of
More informationMANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr.
MANAGEMENT MGMT 0021 THE MANAGEMENT PROCESS 3 cr. An introduction designed to emphasize the basic principles, practices, and terminology essential to the understanding of contemporary business and its
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Company presentation Per Plotnikof, VP Corporate Communications and IR 1 I ALK at a glance Commercial leader and foremost innovator within respiratory allergies
More informationAn exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationAnnual Figures 2017/18. Burgdorf, 24 May 2018
Annual Figures 2017/18 Burgdorf, 24 May 2018 Important information The information contained in this document has not been verified by an independent source. It should be taken with caution and no assurance
More informationThe acquisition of Fortitech
The acquisition of Fortitech Accelerating DSM s strategy to become a full solutions provider in food ingredient blends Investor Relations 8 November 2012 Overview Fortitech at a glance Acquisition rationale
More informationWelcome to the Full -Year Results Press Conference
Welcome to the Full -Year Results Press Conference Disclamer This presentation contains forward looking statements which reflect Management s current views and estimates. The forward looking statements
More informationInvestor Presentation. Q October 26, 2017
Investor Presentation Q1 2018 October 26, 2017 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationFor personal use only. Investor Briefing. Bayswater, 1 st December 2016
Investor Briefing Bayswater, 1 st December 2016 Introduction Samantha Cheetham Chief Executive Officer To be an innovative leader in the dental industry, developing our people and partnering with dentists
More informationPublic Expose. Jakarta, 21 December 2012
Public Expose Jakarta, 21 December 2012 Overview Established in 1911 as a plantation and processing natural rubber company, PT Bakrie Sumatera UNSP Sales (IDR Billion) Plantations Tbk ( UNSP ) now evolving
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference
ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking
More informationTo be the partner of choice Straumann
To be the partner of choice Straumann Gilbert Achermann, CEO Helvea Swiss Equities Conference 11 January 2008, Bad Ragaz Table of contents 1. A snapshot of Straumann 2. Financials 3. Markets and opportunities
More informationValue creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO
Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,
More informationSupplementary Data of Consolidated Financial Statements for the third quarter ended December 31, 2016
Supplementary Data of Financial Statements for the third quarter ended December 31, 2016 January 31, 2017 NITTO DENKO CORPORATION CONTENTS Page Business 1 Segment Information 2 Segment Information By Geographic
More informationAltria Group Inc. Ticker: MO
Altria Group Inc. Ticker: MO Business Description Altria Group Inc. through its subsidiaries manufactures and sells cigarettes, other tobacco products, machine-made large cigars and pipe tobacco. It also
More informationFor personal use only
Sirtex Medical Limited (ASX:SRX) Macquarie Inaugural Annual Emerging Healthcare Conference Mr Gilman Wong, CEO Mr Darren Smith, CFO Dr David Cade, CMO Wednesday, 10 October 2012 Macquarie Securities Group
More informationCochlear Limited 2017 Annual General Meeting Chairman s Address
Cochlear Limited 2017 Annual General Meeting Chairman s Address 17 October 2017 Rick Holliday-Smith Chairman Ladies and gentlemen Financial results Cochlear reported a record net profit of $224 million,
More informationInvestor Day LA&C Region Lausanne, September 29, Jeanne Pollès President, Latin America & Canada Region
Investor Day LA&C Region Lausanne, September 29, 2016 Jeanne Pollès President, Latin America & Canada Region Agenda Regional Overview and Performance Regional Strategies Key Markets Conclusion 2 LA&C Regional
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationDelivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental
Delivering Results POSITIONED FOR GROWTH Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental PAUL GUGGENHEIM CEO, Patterson Dental Former owner and president, Guggenheim Brothers
More informationClosing of Nucletron acquisition Building a stronger position in the cancer care market. September 15, 2011
Closing of Nucletron acquisition Building a stronger position in the cancer care market September 15, 2011 Important step in Elekta s growth strategy Nucletron is the world leader in Brachytherapy and
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationGrowth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts
Growth in core businesses offsets weaker non-interest income April 29, 2005 DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts This presentation is available at www.dbs.com/investor
More informationObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update - All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationSingapore Press Holdings. 1Q FY12 Financial Results 10 January 2012
Singapore Press Holdings 1Q FY12 Financial Results 10 January 2012 Group 1Q FY12 financial highlights 1Q FY12 S$ 000 1Q FY11 S$ 000 Change % Operating Revenue 332,406 318,717 4.3 Operating Profit # 121,230
More informationSlide 1. Investor presentation. Copenhagen 1 November 2018
Slide 1 Investor presentation Copenhagen 1 November 2018 Manato Shirley Ohara, Adelia Stewart diagnosed has type with 2 diabetes type 1 diabetes Kanagawa, New Orleans, Japan Louisiana, US Slide 2 Highlights
More informationNobel Biocare Group Full Year Report 2005
Nobel Biocare Group Full Year Report 2005 Zurich, Switzerland 9 February 2006 Nobel Biocare again outpaces market with record revenue growth of 25% and an EBIT margin of 33.5% in 2005 Revenue for the full
More informationEfforts start to pay off in the fourth quarter
2014 annual sales (1 st January to 31 December 2014) Efforts start to pay off in the fourth quarter Double-digit growth for Food & Beverage in the US (excluding scope effect) Double-digit growth in emerging
More informationEvofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update Phase 3 Trial of Amphora for Hormone-free Contraception Continues to Move Ahead of Schedule; Top Line Data
More informationJEFFERIES 2016 HEALTHCARE CONFERENCE. June 2016
JEFFERIES 2016 HEALTHCARE CONFERENCE June 2016 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More information